Here are the DEF 14A proxy statements from The Chemours Company (CC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CC filings page.
The Chemours Company is asking shareholders to elect eleven directors and approve several governance and compensation proposals at its virtual 2026 annual meeting on April 24, 2026. Items include director elections, an advisory vote on executive pay, a new 2026 Equity and Incentive Plan, and auditor ratification.
The proxy highlights Chemours’ Pathway to Thrive strategy, focused on operational excellence, growth in areas like semiconductors and data centers, portfolio simplification, and long-term risk reduction. In 2025, the company delivered $5.8 billion in net sales, $742 million in Adjusted EBITDA and returned $78 million in dividends, while recording a net loss of $386 million largely due to litigation-related charges.
Board oversight features an independent chair, lead independent director, fully independent committees and strong risk, cybersecurity and sustainability governance. Since 2018, Chemours reports a 76% reduction in fluorinated organic chemical process emissions and a 52% cut in Scope 1 and 2 greenhouse gas emissions, supporting its Trusted Chemistry and 2030 responsibility goals.